RG

Richard B. Gaynor

Director at Alkermes

Dr. Gaynor serves as President, Chief of Research and Development at BioNTech US (previously Neon Therapeutics, Inc.), a leading company in the field of neoantigen-targeted cancer therapies. From November 2016 until May 2020, he was President of Research and Development at Neon Therapeutics. Prior to joining Neon, Dr. Gaynor held clinical development and medical affairs roles at Eli Lilly and Company from August 2002 to October 2016, including serving as Senior Vice President, Clinical Development and Medical Affairs of Lilly Oncology. During his time at Lilly, Dr. Gaynor chaired the Lilly Oncology Research and Development Committee and helped oversee various collaborations, including with General Electric, AstraZeneca, Merck and Bristol-Myers Squibb. Dr. Gaynor started his career in academia, initially serving on the faculty at UCLA School of Medicine for nine years, followed by eleven years at the University of Texas Southwestern Medical School, during which he spent time as the Chief of Hematology-Oncology and Director of the Simmons Cancer Center. Dr. Gaynor holds an M.D. from the University of Texas Southwestern Medical School and completed fellowship training in hematology-oncology at the UCLA School of Medicine. Dr. Gaynor is on the editorial boards of several scientific journals and has an extensive publication record totaling more than 140 scientific articles. He also serves on the boards of directors of Infinity Pharmaceuticals, Inc., a public biopharmaceutical company, and the Damon Runyon Cancer Research Foundation and sits on several committees for the American Association of Cancer Research and other leading cancer organizations.


Org chart

This person is not in the org chart